Magenta Therapeutics, Inc. Uncategorized Contracts & Agreements
13 Contracts & Agreements
- Amendment to Offer Letter, dated September 11, 2023, by and between Dianthus Therapeutics OpCo, Inc. and Simrat Randhawa (Filed With SEC on March 21, 2024)
- Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on March 21, 2024)
- Amendment to Offer Letter, dated September 11, 2023, by and between OpCo and Edward Carr (Filed With SEC on September 12, 2023)
- Amendment to Offer Letter, dated September 11, 2023, by and between OpCo and Ryan Savitz (Filed With SEC on September 12, 2023)
- Amendment to Offer Letter, dated September 11, 2023, by and between OpCo and Marino Garcia (Filed With SEC on September 12, 2023)
- Contingent Value Rights Agreement, dated September 11, 2023, by and between the Company and the Rights Agent (Filed With SEC on September 12, 2023)
- Form of Contingent Value Rights Agreement (Filed With SEC on May 3, 2023)
- Form of Lock-Up Agreement (Filed With SEC on May 3, 2023)
- Form of Magenta Support Agreement (Filed With SEC on May 3, 2023)
- Form of Dianthus Support Agreement (Filed With SEC on May 3, 2023)
- Description of Securities of the Registrant (Filed With SEC on March 3, 2020)
- Agreement, dated as of May 31, 2018, by and between the Registrant and The Richmond Group, Inc (Filed With SEC on November 8, 2018)
- Clinical Trial Agreement by and between Regents of the University of Minnesota and the Registrant, dated as of January 22, 2018 (Filed With SEC on May 24, 2018)
